Small Pharma’s CEO, George Tziras, on the commercialisation of psychedelic healthcare
It is a pivotal time for Small Pharma, as it anticipates data from its Phase IIa trial with lead candidate SPL026 – its proprietary DMT formulation.
As Small Pharma looks towards the latter stages of drug development, it has recalibrated its leadership accordingly, appointing George Tziras CEO in July.
Tziras, previously Chief Business Officer, has over 15 years’ experience in investment banking and capital markets, holding the position of Executive Director at Goldman Sachs before joining the company.
Since the appointment, Small Pharma has seen its share price surge 100%. PSYCH spoke with the new CEO on capital markets and the commercialisation of psychedelic healthcare.READ MORE